BioSpace News Archive

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, reported that on July 6, 2021, the Company granted non-qualified stock options to purchase an aggregate of 177,400 shares of the Company’s common stock to nine new employees.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it will participate in a Fireside Chat with H.C. Wainwright at 11 a.m. Eastern Time on Monday, July 12, 2021.

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has joined the Rare Disease Company Coalition,

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced it will participate in the Annual World Congress of the Society for Brain Mapping and Therapeutics, which will be held from July 8-11th in Los Angeles, California.

Growing prevalence of dental disorders among a considerable population is driving the market revenue growth.

Factors contributing to the growth of the defibrillator market share are; increase in implementation of technologically advanced defibrillators, upward demand for superiority medical care and cardiovascular.

High disease prevalence across the globe coupled with ongoing research & development is expected to stimulate market growth.

Rising government funding for clinical trials, increased application of software solutions in clinical trials and clinical research, the growing customer base for e-Clinical solutions, are key factors contributing to the high CAGR of eClinical Solutions during the forecast period.

ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic and other rare disorders today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for ASC618, an investigational second-generation gene therapy for patients with severe and moderately severe hemophilia A.

Trial will be conducted at the Israeli Medical Center for Alzheimer’s and will evaluate the safety, tolerability and efficacy of SCI-110